ADAM17在胃癌中的研究进展  

Research Progress of ADAM17 in Gastric Cancer

作　　者：杨梦娇 袁浩[2,3] 郑亚 王玉平 郭庆红[2,3] YANG Mengjiao;YUAN Hao;ZHENG Ya;WANG Yuping;GUO Qinghong(Lanzhou University,First Clinical Medical College,Lanzhou 730000,China;Department of Gastroenterology,the First Hospital of Lanzhou University,Lanzhou 730000,China;Gansu Province Clinical Research Center for Digestive Diseases,Lanzhou 730000,China)

机构地区：[1]兰州大学第一临床医学院,兰州730000 [2]兰州大学第一医院消化科,兰州730000 [3]甘肃省消化疾病临床研究中心,兰州730000

出　　处：《协和医学杂志》2024年第2期375-381,共7页Medical Journal of Peking Union Medical College Hospital

摘　　要：胃癌是最常见的恶性肿瘤之一,患者多采用手术、放化疗及免疫治疗,但临床疗效及预后欠佳。去整合素⁃金属蛋白酶(a disintegrin and metalloproteinase,ADAM)17作为ADAMs家族的重要成员,在胃癌组织中的表达显著高于癌旁组织,并通过介导EGFR和TNF⁃α、TGF⁃β/Smad、Notch和Wnt、FoxM1⁃ADAM17以及EGFR/ERK/SP1等信号通路参与胃癌的发生发展,其高表达与预后不良密切相关,提示ADAM17可作为胃癌的生物学指标,预测胃癌发展,有望成为胃癌新的治疗靶点。本文就ADAM17在胃癌发展中的作用机制、治疗及预测研究进展作一综述,以期为胃癌临床诊疗提供新思路。Gastric cancer is one of the most common malignant tumors in the world.Patients with gastric cancer are often treated by surgery,radiotherapy,chemotherapy or immunotherapy,but the clinical efficacy and prognosis are poor.As an important member of ADAMs family,a disintegrin and metalloprotease 17(ADAM17)is significantly more highly expressed in gastric cancer than in adjacent tissues.It participates in the occurrence and development of gastric cancer by mediating EGFR,TNF⁃α,TGF⁃β/Smad,Notch and Wnt,FoxM1⁃ADAM17 and EGFR/ERK/SP1.The high expression of ADAM17 is also closely related to the poor prognosis of gastric cancer,suggesting that ADAM17 can be used as a biological index to predict the develop⁃ment and prognosis of gastric cancer and has great potential to become a new therapeutic target for gastric canc⁃er.In this paper,the mechanism,treatment and prognosis of ADAM17 in the development of gastric cancer are reviewed,in order to provide new ideas for clinical diagnosis and treatment of gastric cancer.

关 键 词：胃癌 去整合素⁃金属蛋白酶17 作用机制 靶向治疗 预后 

分 类 号：R735[医药卫生—肿瘤]